Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy

Rutika A. Kokate, Pankaj Chaudhary, Xiangle Sun, Sanjay I. Thamake, Sayantan Maji, Rahul Chib, Jamboor K. Vishwanatha, Harlan P. Jones

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background: Delivery of PLGA (poly [D, L-lactide-co-glycolide])-based biodegradable nanoparticles (NPs) to antigen presenting cells, particularly dendritic cells, has potential for cancer immunotherapy. Materials & methods: Using a PLGA NP vaccine construct CpG-NP-Tag (CpG-ODN-coated tumor antigen [Tag] encapsulating NP) prepared using solvent evaporation technique we tested the efficacy of ex vivo and in vivo use of this construct as a feasible platform for immune-based therapy. Results: CpG-NP-Tag NPs were avidly endocytosed and localized in the endosomal compartment of bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells exposed to CpG-NP-Tag NPs exhibited an increased maturation (higher CD80/86 expression) and activation status (enhanced IL-12 secretion levels). In vivo results demonstrated attenuation of tumor growth and angiogenesis as well as induction of potent cytotoxic T-lymphocyte responses. Conclusion: Collectively, results validate dendritic cells stimulatory response to CpG-NP-Tag NPs (ex vivo) and CpG-NP-Tag NPs' tumor inhibitory potential (in vivo) for therapeutic applications, respectively.

Original languageEnglish
Pages (from-to)479-494
Number of pages16
JournalNanomedicine
Volume11
Issue number5
DOIs
StatePublished - Mar 2016

Keywords

  • DCs
  • NP
  • breast cancer
  • cancer vaccines
  • dendritic cells
  • immunotherapy
  • nanoparticle

Fingerprint Dive into the research topics of 'Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy'. Together they form a unique fingerprint.

  • Cite this